Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0IX0N
|
||||
| Former ID |
DNC011569
|
||||
| Drug Name |
N*1*-(5-Methyl-2-nitro-phenyl)-butane-1,4-diamine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C11H17N3O2
|
||||
| Canonical SMILES |
CC1=CC(=C(C=C1)[N+](=O)[O-])NCCCCN
|
||||
| InChI |
1S/C11H17N3O2/c1-9-4-5-11(14(15)16)10(8-9)13-7-3-2-6-12/h4-5,8,13H,2-3,6-7,12H2,1H3
|
||||
| InChIKey |
ANIBJVLRYPKMKX-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Nitric-oxide synthase, brain | Target Info | Inhibitor | [1] | |
| BioCyc Pathway | Citrulline-nitric oxide cycle | ||||
| KEGG Pathway | Arginine and proline metabolism | ||||
| Metabolic pathways | |||||
| Calcium signaling pathway | |||||
| Phagosome | |||||
| Circadian entrainment | |||||
| Long-term depression | |||||
| Salivary secretion | |||||
| Alzheimer's disease | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| NetPath Pathway | EGFR1 Signaling Pathway | ||||
| PANTHER Pathway | CCKR signaling map ST | ||||
| PathWhiz Pathway | Arginine and Proline Metabolism | ||||
| Reactome | ROS production in response to bacteria | ||||
| Nitric oxide stimulates guanylate cyclase | |||||
| WikiPathways | Monoamine Transport | ||||
| Myometrial Relaxation and Contraction Pathways | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||||
| Spinal Cord Injury | |||||
| Alzheimers Disease | |||||
| Effects of Nitric Oxide | |||||
| Serotonin Transporter Activity | |||||
| References | |||||
| REF 1 | J Med Chem. 1998 Jul 2;41(14):2636-42.Nitroaromatic amino acids as inhibitors of neuronal nitric oxide synthase. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.